Changes in blood counts after the administration of granulocyte-colony-stimulating factor and the collection of peripheral blood stem cells from healthy donors
- PMID: 8701454
- DOI: 10.1046/j.1537-2995.1996.36796323058.x
Changes in blood counts after the administration of granulocyte-colony-stimulating factor and the collection of peripheral blood stem cells from healthy donors
Abstract
Background: After the collection of granulocyte-colony-stimulating factor (G-CSF)-mobilized peripheral blood stem cells from healthy donors, the donor platelet counts fall. However, the magnitude and duration of this decrease are not known.
Study design and methods: Sixty healthy people were given G-CSF (5, 7.5, or 10 micrograms/kg/day) for 5 days (Days 1-5), and 1 peripheral blood stem cell component was collected on Day 6. The platelet count, white cell count, absolute neutrophil count, hematocrit, and red cell count were measured before administration of G-CSF (Day 0), before collection of peripheral blood stem cells on Day 6, and on Days 8, 10, 13, 16, and 20.
Results: The platelet count fell from 261 +/- 47 x 10(9) cells per L on Day 0 to 159 +/- 30 x 10(9) cells per L on Day 8 (p < 0.0001) and reached its lowest level on Day 10 (146 +/- 30 x 10(9)/L; p < 0.001). Compared to Day 0 levels, the platelet count was lower on Day 13 (185 +/- 49 x 10(9)/L, p < 0.001), was the same on Day 16 (270 +/- 53 x 10(9)/L), and was greater on Day 20 (333 +/- 60 x 10(9)/L, p < 0.0001). The white cell count returned to pretreatment values on Day 13, and the absolute neutrophil count returned to pretreatment values on Day 10 (Day 0 white cell count = 6.05 +/- 1.59 x 10(9)/L and Day 0 absolute neutrophil count = 3.97 +/- 1.52 x 10(9)/L). On Day 20, both were less than pretreatment values (white cell count = 5.14 +/- 1.24 x 10(9)/L, p = 0.0007 and absolute neutrophil count = 3.20 +/- 1.24 x 10(9)/L, p = 0.0036). The red cell counts on Day 16 (4.52 +/- 0.41 x 10(12)/L) and Day 20 (4.42 +/- 0.39 x 10(12)/L) were less than Day 0 values (4.73 +/- 0.43 x 10(12)/L, p = 0.008 and p < 0.0001, respectively). The hematocrit on Day 20 (39.2 +/- 3.2%) was also less than that on Day 0 (41.2 +/- 4.8%; p = 0.01). The changes in these blood counts were not affected by the dose of the G-CSF.
Conclusion: After stimulation with granulocyte-colony-stimulating factor and the collection or peripheral blood stem cells, the platelet counts in normal donors were decreased for at least 7 days (Days 6-13). Two weeks after collection of peripheral blood stem cells (Day 20), platelet production was increased, but the production of neutrophils and red cells was decreased. If two or more peripheral blood stem cell components are collected, then the platelet count should be measured after the second and subsequent collections. Further studies on the long-term effect of G-CSF on blood counts are needed.
Comment in
-
Allogeneic marrow reconstitution using peripheral blood stem cells: the dawn of a new era.Transfusion. 1996 Jul;36(7):585-9. doi: 10.1046/j.1537-2995.1996.36796323056.x. Transfusion. 1996. PMID: 8701452 No abstract available.
Similar articles
-
Treatment of normal individuals with granulocyte-colony-stimulating factor: donor experiences and the effects on peripheral blood CD34+ cell counts and on the collection of peripheral blood stem cells.Transfusion. 1996 Jul;36(7):601-10. doi: 10.1046/j.1537-2995.1996.36796323059.x. Transfusion. 1996. PMID: 8701455
-
Collection of two peripheral blood stem cell concentrates from healthy donors.Transfus Med. 1999 Mar;9(1):37-50. doi: 10.1046/j.1365-3148.1999.009001037.x. Transfus Med. 1999. PMID: 10216904 Clinical Trial.
-
Comparison of the potency of glycosylated and nonglycosylated recombinant human granulocyte colony-stimulating factors in neutropenic and nonneutropenic CD rats.Cancer Chemother Pharmacol. 1997;39(3):259-66. doi: 10.1007/s002800050570. Cancer Chemother Pharmacol. 1997. PMID: 8996530
-
Blood stem cell procurement: donor safety issues.Bone Marrow Transplant. 1998 Jun;21 Suppl 3:S35-9. Bone Marrow Transplant. 1998. PMID: 9712491 Review.
-
[Collection of hematopoietic progenitor cells from healthy donors].Acta Med Croatica. 2009 Jun;63(3):237-44. Acta Med Croatica. 2009. PMID: 19827352 Review. Croatian.
Cited by
-
G-CSF in Healthy Allogeneic Stem Cell Donors.Transfus Med Hemother. 2013 Aug;40(4):225-35. doi: 10.1159/000354196. Epub 2013 Jul 22. Transfus Med Hemother. 2013. PMID: 24179471 Free PMC article. Review.
-
SMAD signaling regulates CXCL12 expression in the bone marrow niche, affecting homing and mobilization of hematopoietic progenitors.Stem Cells. 2014 Nov;32(11):3012-22. doi: 10.1002/stem.1794. Stem Cells. 2014. PMID: 25069965 Free PMC article.
-
Quantifying Drug-Induced Bone Marrow Toxicity Using a Novel Haematopoiesis Systems Pharmacology Model.CPT Pharmacometrics Syst Pharmacol. 2019 Nov;8(11):858-868. doi: 10.1002/psp4.12459. Epub 2019 Oct 20. CPT Pharmacometrics Syst Pharmacol. 2019. PMID: 31508894 Free PMC article.
-
Protecting the Health and Safety of Cell and Tissue Donors.ISBT Sci Ser. 2015 Apr 1;10(Suppl 1):108-114. doi: 10.1111/voxs.12150. ISBT Sci Ser. 2015. PMID: 25937830 Free PMC article.
-
Is It Better to Mobilize Hematopoietic Stem Cells With Pegfilgrastim in Healthy Donors During Allogeneic Hematopoietic Stem Cell Transplantation?Front Oncol. 2020 Sep 3;10:1598. doi: 10.3389/fonc.2020.01598. eCollection 2020. Front Oncol. 2020. PMID: 33014813 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical